J S M Zimmermann1, J C Radosa2, M P Radosa3, P Sklavounos2, P A Schweitzer2, E F Solomayer2. 1. Department of Gynecology and Obstetrics, Saarland University Hospital, Kirrbergerstraße 100, 66421, Homburg, Saar, Germany. Julia.Zimmermann@uks.eu. 2. Department of Gynecology and Obstetrics, Saarland University Hospital, Kirrbergerstraße 100, 66421, Homburg, Saar, Germany. 3. Department of Gynecology and Obstetrics, Klinikum Bremen Nord, Bremen, Germany.
Abstract
PURPOSE: As data on this topic are sparse and contradictory, we aimed to ascertain the opinions of the members of the German Society of Gynecologic Endoscopy (AGE) regarding the use of robotic surgery in the treatment of ovarian malignancies. METHODS: In 2015, an anonymous questionnaire was sent to AGE members to assess their views on the treatment of ovarian malignancies by robotic surgery according to T stage and the current treatment practices in their facilities. RESULTS: Of the 228 respondents, 132 (58%) were fellows or attending physicians and 156 (68%) worked at university hospitals or tertiary referral centers. Most [n = 218 (96%)] respondents reported treating < 10% of their patients using robotic surgery. Respondents felt that T1 and borderline ovarian tumors, but not T2 (51%) or T3/4 (76%) tumors, should and could be treated by robot surgery. 162 (71%) respondents considered the currently available data on this subject to be insufficient, and 42% indicated their willingness to participate in clinical studies on the applicability of robotic surgery to the treatment of T1/2 ovarian tumors. CONCLUSION: The majority of AGE members surveyed considered robotic surgery to be an option for the treatment of T1 ovarian malignancies and borderline ovarian tumors. However, prospective randomized studies are needed to determine the relevance of robotic surgery in this context.
PURPOSE: As data on this topic are sparse and contradictory, we aimed to ascertain the opinions of the members of the German Society of Gynecologic Endoscopy (AGE) regarding the use of robotic surgery in the treatment of ovarian malignancies. METHODS: In 2015, an anonymous questionnaire was sent to AGE members to assess their views on the treatment of ovarian malignancies by robotic surgery according to T stage and the current treatment practices in their facilities. RESULTS: Of the 228 respondents, 132 (58%) were fellows or attending physicians and 156 (68%) worked at university hospitals or tertiary referral centers. Most [n = 218 (96%)] respondents reported treating < 10% of their patients using robotic surgery. Respondents felt that T1 and borderline ovarian tumors, but not T2 (51%) or T3/4 (76%) tumors, should and could be treated by robot surgery. 162 (71%) respondents considered the currently available data on this subject to be insufficient, and 42% indicated their willingness to participate in clinical studies on the applicability of robotic surgery to the treatment of T1/2 ovarian tumors. CONCLUSION: The majority of AGE members surveyed considered robotic surgery to be an option for the treatment of T1 ovarian malignancies and borderline ovarian tumors. However, prospective randomized studies are needed to determine the relevance of robotic surgery in this context.
Authors: Julia Caroline Radosa; Marc Philipp Radosa; Pascal Albert Schweitzer; Ingolf Juhasz-Boess; Stefan Rimbach; Erich-Franz Solomayer Journal: Arch Gynecol Obstet Date: 2018-03-08 Impact factor: 2.344
Authors: A Lucidi; V Chiantera; V Gallotta; A Ercoli; G Scambia; A Fagotti Journal: Best Pract Res Clin Obstet Gynaecol Date: 2017-05-10 Impact factor: 5.237
Authors: Robert E Bristow; Rafael S Tomacruz; Deborah K Armstrong; Edward L Trimble; F J Montz Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544
Authors: A Fagotti; F Fanfani; G Vizzielli; V Gallotta; A Ercoli; A Paglia; B Costantini; M Vigliotta; G Scambia; G Ferrandina Journal: Gynecol Oncol Date: 2009-10-28 Impact factor: 5.482
Authors: Oliver Zivanovic; Yukio Sonoda; John P Diaz; Douglas A Levine; Carol L Brown; Dennis S Chi; Richard R Barakat; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2008-10-16 Impact factor: 5.482